WALTHAM - Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH ('Navigo'), a premier protein engineering company specializing in novel affinity ligand development, today announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines.
The program has entered stage two, which is focused on both scaling up the manufacturing of this ligand, and on the development and validation of the related affinity chromatography resin. The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines. Repligen anticipates that the final resin product will be commercially available in early 2021.
Ralf Kuriyel, Repligen Senior Vice President R&D said, 'We are very pleased to report this progress through our partnership with Navigo Proteins, which enables us to rapidly screen and develop commercially viable affinity ligands and resins to support the development and scale-up of COVID-19 vaccines. We look forward to providing additional feedback in the coming months as customers evaluate the potential of this chromatography ligand and resin in COVID applications.'
Dr. Henning Afflerbach, CEO of Navigo Proteins said, 'This joint endeavor is the logical continuation of our journey to develop platform-based purification solutions for biopharmaceutical downstream processing. Our affinity chromatography technology - Precision Capturing- is a solution to cope with ever increasing regulatory and capacity requirements of the entire biopharmaceutical manufacturing industry, including vaccines.'
With a surge in the demand for global coronavirus vaccine manufacturing capacity, Repligen and Navigo initiated development of a robust and scalable purification product for COVID-19 vaccine manufacturing. Spike proteins are a characterizing feature of SARS-CoV-2, the virus that causes COVID-19. The spike protein is the primary antigen being evaluated in clinical trials to induce an immune response as a COVID-19 vaccine.
Under their strategic partnership, Repligen and Navigo deployed their expertise in discovery, development, manufacturing and commercialization of customized affinity ligands and chromatography resins to provide a rapid purification solution to support the development and scale-up of potential COVID-19 vaccines.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, MA (USA), and we have additional administrative and manufacturing operations in Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Clifton Park, NY; Lund, Sweden; Breda, The Netherlands and Ravensburg, Germany.
About Navigo Proteins Gmb H
Navigo Proteins is a premier protein engineering company, specialized in creating novel affinity ligands for PRECISION CAPTURING and PRECISION TARGETING. These proteins serve either as highly specific binders for custom affinity purification of complex biologics or as ligands in active biotherapeutic or diagnostic molecules. Navigo's unique protein engineering expertise is based on the company's proprietary platform of different small and stable, yet highly engineerable scaffold proteins. The company's PRECISION CAPTURING platform creates affinity ligands and chromatography resins that can specifically bind and purify literally any biologic, even without Fc part and notably enables one-step platform downstream processes. PRECISION CAPTURING is based on Protein A-derived scaffold variants, combining the industry-accepted virtues of protein A with entirely novel selectivity & mild elution conditions. PRECISION CAPTURING is applicable for purifying recombinant proteins, monoclonal antibodies, viruses, VLPs and other biologics. Navigo works with renowned partners to convert its affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing.
Contact:
Sondra S. Newman
Tel: (781) 419-1881
Email: snewman@repligen.com
REPLIGEN CORPORATION 
